Together, this study indicates that HSPC-mediated lentiviral gene therapy induces immune tolerance to GAA and that subsequent treatment with ERT is safe and efficacious, offering a promising scenario for the clinical development of lentiviral gene therapy for the treatment of Pompe disease. This evidence concerns the gene PSMA7 and glycogen storage disease II.